Cancer Cachexia Market size was over USD 2.49 billion in 2024 and is projected to cross USD 4.58 billion by the end of 2037, growing at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cancer cachexia is estimated at USD 2.59 billion.
Over the course of the projection period, which runs from 2024 to 2036, the growing geriatric population is anticipated to support market expansion. The percentage of the population that is 60 years of age or older is rising. There were one billion individuals sixty years of age or older in the world in 2019. By 2030, there will be 1.4 billion, and by 2050, there will be 2.1 billion. Elderly people's weakened immune systems make them more prone to diseases, which is predicted to accelerate the market's growth pace.
In addition to these, the market for cancer cachexia will also grow as a result of increased awareness-raising campaigns by public and private institutions. The market for cancer cachexia will also grow as a result of developments in the treatment of cancer cachexia and sedentary lifestyles.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
4.8% |
Base Year Market Size (2024) |
USD 2.49 billion |
Forecast Year Market Size (2037) |
USD 4.58 billion |
Regional Scope |
|
Mode of Action (Weight Loss Stabilizers, Appetite Stimulants)
The weight loss stabilizers segment in the cancer cachexia market is anticipated to hold the largest share of about 55% during the forecast period. Because cancer patients experience extreme weight loss, weight loss stabilizers dominate the market for cancer cachexia. Physicians offer weight loss stabilizers to counteract weight loss and improve the quality of life for cancer patients experiencing cachexia. Cytokine inflammation, tissue loss, wasting syndrome, and cystic fibrosis are the hallmarks of cachexia. To enhance the quality of life for cancer patients, it is imperative to counteract weight loss in this condition. Cachexia results from uncontrollably losing muscle mass, dying from radiation and chemotherapy, and seeing an 85% increase in the last one to two weeks. Furthermore, as the condition progresses, 45% of patients lose more than 10% of their initial weight. Weight stabilizers are advised by doctors to prevent cachexia.
Drugs (Progestogens, Dronabinol, Mega Sterol Acetate, Corticosteroids)
The progestogens segment is expected to hold 48% share of the cancer cachexia market by 2037. The primary reasons for this are progestogen's cost-effectiveness, tolerability, and efficacy in treating cachexia. Since progestogens are more effective than other medications, it is anticipated that demand for them will stay high over the coming years. In addition to these, the most efficient and painless treatment for cancer cachexia was progestogens. As a result, it will still be significant in the progestogens market sector. The goals of the current treatments are cancer cachexia palliation as well as patient and family relief.
Our in-depth analysis of the global cancer cachexia market includes the following segments:
Drugs |
|
Mode of Action |
|
Indication |
|
Route of Administration |
|
Dosage Form |
|
End-Users |
|
Distribution Channel |
|
North America Market Forecast
North America cancer cachexia market is expected to hold largest revenue share of about 30% during the forecast period. The market for cancer cachexia is dominated by North America due to the region's rising prevalence of chronic illnesses like cancer and expanding knowledge of cachexia treatments. The availability of treatment choices and growing healthcare costs will also accelerate the market's development pace in this region. North America is anticipated to lead the market because of the region's high cancer and cancer cachexia rates, abundance of pharmaceutical companies, and evolving approaches to cancer patient treatment. Mexico is estimated to have about 195,499 new cases of cancer, based on a survey in 2020. In addition, the American Cancer Society 2022 projects that there will be 1.9 million new cancer diagnoses in the US in 2022.
APAC Market Statistics
Cancer cachexia market in the Asia Pacific is predicted to account for 27% of the revenue share by the end of 2037. The growth of the market is because this area is home to generic producers. Additionally, the expansion of government initiatives and the construction of healthcare infrastructure will accelerate the growth rate of this market in this region.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?